
A
Lanthanum carbonate 3000 mg/day
Placebo
a,b
a,b,c,d,e
a,e
a,e
a,c,d,e
a,c,e
e
Visit
Screening
1
Baseline
2
3
4
5
Final visit
Follow-up call
Week
–2
0
1
2
8
12
16
B
Randomized
n = 35
Safety set
Placebo
n = 12
Safety set
Lanthanum carbonate
n = 23
Discontinued n = 2
• Protocol violation (eGFR < 30 ml/min/1.73 m²) n = 1
• Death n = 1
Excluded n = 4
• Compliance < 60% n = 2
• Prohibited medication (calcium-containing compound) n = 1
• C-terminal FGF23 ≤ 50 RU/ml n = 1
Per protocol
(analysis set)
Placebo
n = 12
Per protocol
(analysis set)
Lanthanum carbonate
n = 17